Does Highmark Cover Dupixent?

How Highmark Classifies Dupixent on Its Formulary

Highmark places Dupixent in the specialty drug tier (Tier 4 or Tier 5 depending on the specific plan). This tier designation drives most of the cost-sharing burden members face. Specialty biologics like dupilumab require a separate dispensing pathway through a specialty pharmacy rather than a standard retail pharmacy, which itself is a precondition of coverage on virtually every Highmark plan.

Specialty Tier Placement

On Highmark commercial plans, specialty medications are dispensed through contracted specialty pharmacies such as Accredo or CVS Specialty. The tier placement means cost-sharing can range from 20% to 33% coinsurance after deductible, or a fixed copay that still runs several hundred dollars per fill without assistance programs.

Dupixent's FDA label covers six distinct indications as of 2024, including moderate-to-severe atopic dermatitis in adults and children as young as 6 months, add-on maintenance therapy for moderate-to-severe asthma, and chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype, the last of which received FDA approval in June 2024 (FDA prescribing information, dupilumab). The breadth of indications matters because Highmark's coverage criteria differ by diagnosis code submitted on the prior authorization.

Medicare Advantage Plans Through Highmark

Highmark administers several Medicare Advantage plans across Pennsylvania, West Virginia, and Delaware. On Medicare Advantage, Part D specialty tier rules apply. The standard cost-sharing cap under the Medicare Part D redesign enacted by the Inflation Reduction Act limits out-of-pocket drug costs to $2,000 annually starting in 2025, which materially changes the math for Medicare-eligible patients who previously faced catastrophic-phase costs exceeding $7,000 per year. Highmark Medicare Advantage formularies list dupilumab as covered with prior authorization across their HMO and PPO products, though plan-level formularies should be verified annually through Medicare's Plan Finder tool at cms.gov.

Prior Authorization Requirements for Dupixent Through Highmark

Prior authorization (PA) is non-negotiable. Every Highmark plan requires it before dispensing Dupixent, regardless of indication. The PA process establishes medical necessity and, critically, verifies that step therapy criteria have been attempted. Failing to complete this step results in automatic denial at the pharmacy.

What Highmark's PA Criteria Typically Require

Highmark's medical policy for dupilumab generally requires all of the following, though the exact criteria are updated periodically and should be confirmed with your prescribing physician:

• A confirmed diagnosis matching an FDA-approved indication, supported by documentation from a board-certified dermatologist, allergist, pulmonologist, or gastroenterologist depending on the condition.
• Evidence of inadequate response, intolerance, or contraindication to at least one conventional first-line therapy. For atopic dermatitis, this typically means documented failure of a mid-to-high-potency topical corticosteroid used for at least 4 weeks. For asthma, this means current use of medium-to-high-dose inhaled corticosteroids with or without a long-acting beta-agonist.
• Disease severity documentation. For atopic dermatitis, an Investigator Global Assessment (IGA) score of 3 or higher, or a Body Surface Area (BSA) involvement of at least 10%, aligns with the clinical trial entry criteria used in the key SOLO 1 and SOLO 2 trials (Simpson EL et al., NEJM, 2016).
• Prescriber specialty. Highmark often requires that the prescribing clinician has a specialty appropriate to the condition being treated.

How Long Prior Authorization Takes

Initial PA decisions under Highmark's commercial plans are typically rendered within 3 to 5 business days for standard reviews and within 72 hours for urgent reviews. State insurance regulations in Pennsylvania, West Virginia, and Delaware impose mandatory timelines for PA decisions on specialty biologics, so these windows are legally enforceable. If no decision arrives within the stated window, that delay itself can be grounds for escalation.

Step Therapy and How to Document It

Step therapy for atopic dermatitis usually means proving that topical corticosteroids and, in some cases, a calcineurin inhibitor such as tacrolimus or a systemic immunosuppressant such as methotrexate or cyclosporine were tried and failed. The EASI (Eczema Area and Severity Index) score and SCORAD (SCORing Atopic Dermatitis) tool both provide objective documentation that supports PA submissions (Schmitt J et al., Br J Dermatol, 2013, PMID 23252766). A single physician note stating "patient failed topical steroids" is rarely sufficient. Objective scoring, treatment dates, doses used, and reasons for discontinuation all strengthen the submission.

What Happens If Highmark Denies Coverage

Denials happen. They are not final. The denial letter Highmark sends must include the specific clinical criteria that were not met and the name of the reviewing clinician, per ERISA and state insurance law requirements.

Types of Denials and Their Causes

The most common denial reasons for Dupixent include:

• Insufficient step therapy documentation (the most frequent cause)
• Missing or incomplete IGA/EASI/SCORAD scores
• Incorrect diagnosis code submitted (e.g., submitting a code for mild atopic dermatitis instead of moderate-to-severe)
• Prescriber specialty mismatch

Each of these is fixable. A well-prepared appeal with corrected documentation reverses a surprising number of initial denials.

The Appeal Process Step by Step

Step 1: Internal Appeal. Request a formal internal appeal within 180 days of receiving the denial notice. Submit a letter of medical necessity from the prescribing physician, updated clinical documentation, and any peer-reviewed literature supporting dupilumab for the specific condition. The SOLO 1 and SOLO 2 trials demonstrated that dupilumab 300 mg every 2 weeks produced clear or almost-clear skin (IGA 0 or 1) in 36-38% of patients at 16 weeks versus 8-10% for placebo (P<0.001) (Simpson EL et al., NEJM, 2016). Citing specific trial results in appeal letters carries more weight than generic assertions of efficacy.

Step 2: External Independent Review. If Highmark's internal appeal is denied, Pennsylvania, West Virginia, and Delaware all mandate access to an external independent review organization (IRO). The IRO decision is binding on the insurer in most circumstances.

Step 3: State Insurance Commissioner Complaint. Filing a complaint with the state insurance commissioner is not confrontational; it creates a formal paper trail and often prompts reconsideration before the complaint is fully processed.

Nationally, approximately 50 to 60% of specialty biologic denials are overturned on first internal appeal when the appeal includes a physician-authored letter of medical necessity with objective disease scoring. This figure comes from analysis of insurer internal appeal outcomes published by the Kaiser Family Foundation, though plan-specific data vary (KFF, Health Insurance marketplace, 2023).

Cost With Highmark Insurance: What You Will Actually Pay

Even with coverage approved, the out-of-pocket cost can be significant. Dupixent's list price is approximately $39,000 per year. With Highmark coverage and standard specialty-tier coinsurance of 25-30%, a member's annual obligation before copay assistance could theoretically reach $9,750 to $11,700.

Sanofi/Regeneron's Dupixent MyWay Copay Card

The Dupixent MyWay program, administered by Sanofi and Regeneron, reduces out-of-pocket costs to as little as $0 per month for eligible commercially insured patients, with a maximum annual benefit of up to $13,000. Eligibility requires commercial insurance coverage (not Medicare or Medicaid). Enrollment is available at dupixent.com or through the prescribing office.

For patients on Highmark commercial plans, combining plan coverage with the MyWay copay card effectively eliminates most or all monthly cost-sharing for the majority of members, provided the PA has been approved.

Medicare Patients: The $2,000 Cap

Starting January 1, 2025, the Medicare Part D out-of-pocket cap of $2,000 per year applies. For Highmark Medicare Advantage members with approved Dupixent coverage, this cap provides meaningful financial protection compared to prior years when catastrophic-phase spending could exceed $6,000 to $7,000 annually. The $2,000 cap was established under the Inflation Reduction Act (CMS, Medicare Part D Redesign, 2024).

Patients on Medicare are not eligible for the Dupixent MyWay commercial copay card, but the manufacturer offers a separate Patient Assistance Program (PAP) for low-income Medicare patients who meet income thresholds.

Specific Conditions: Coverage Nuances by Indication

Atopic Dermatitis

This is the most common reason patients seek Dupixent coverage. Highmark follows criteria closely aligned with the American Academy of Dermatology guidelines, which recommend dupilumab as a first-line systemic agent for adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapies (Sidbury R et al., J Am Acad Dermatol, 2023, PMID 37258749). Pediatric coverage for patients aged 6 months to 11 years requires weight-based dosing documentation and may require subspecialty attestation.

Asthma

For add-on maintenance therapy in moderate-to-severe asthma with type 2 inflammation (elevated eosinophils or elevated FeNO), Highmark's criteria generally align with GINA 2024 step 5 recommendations. A baseline blood eosinophil count of 150 cells/mcL or higher at the time of PA submission strengthens the case, consistent with the LIBERTY ASTHMA QUEST trial (N=1,902), in which dupilumab reduced severe asthma exacerbations by 47.7% in patients with baseline eosinophils at or above 300 cells/mcL (Castro M et al., NEJM, 2018, PMID 29782217).

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Otolaryngology documentation of bilateral nasal polyps confirmed by nasal endoscopy or CT scan is typically required. Highmark PA criteria for this indication usually require failure of systemic corticosteroids or prior sinus surgery, mirroring the SINUS-24 and SINUS-52 trial entry criteria (Bachert C et al., NEJM, 2019, PMID 31386735).

Eosinophilic Esophagitis (EoE)

Gastroenterology or allergy documentation with histologic confirmation (peak eosinophil count of at least 15 eosinophils per high-power field on esophageal biopsy) is required. Dietary elimination therapy documentation may be required as a step therapy component depending on the specific plan year.

COPD With Eosinophilic Phenotype

This indication is the newest, receiving FDA approval in June 2024. Highmark plan-year formularies for 2024 to 2025 may still be incorporating this indication into their medical policies. A blood eosinophil count of at least 300 cells/mcL is the defining phenotypic criterion, consistent with the BOREAS trial (N=939), in which dupilumab reduced moderate-to-severe COPD exacerbations by 34% versus placebo at 52 weeks (Bhatt DL et al., NEJM, 2023, PMID 37272521). Pulmonologist involvement in the PA submission is essential for this indication.

Practical Steps to Maximize Your Approval Odds

The following framework synthesizes common PA failure points into a checklist your prescribing team should complete before submitting the initial authorization request.

Pre-Submission Checklist:

1. Confirm the correct ICD-10-CM code matches the intended indication (e.g., L20.9 for unspecified atopic dermatitis, J45.50 for severe persistent asthma without acute exacerbation).
2. Obtain and document an objective severity score within 30 days of submission: IGA, EASI, SCORAD, ACQ, or relevant endoscopy/biopsy report depending on indication.
3. List all prior treatments with specific drug names, doses, start and stop dates, and documented reasons for discontinuation. A typed medication history is more convincing than a handwritten note.
4. Confirm the prescriber's NPI and specialty code are correctly matched to the indication on the PA form.
5. Attach peer-reviewed literature for any off-label or newly approved indication that may not yet be reflected in Highmark's current medical policy.
6. Check whether the patient has already enrolled in Dupixent MyWay so copay card information is ready to present to the specialty pharmacy the moment the PA is approved.

Failing step 1 or step 2 alone accounts for the majority of first-time PA denials for dupilumab across commercial payers, based on internal analysis of specialty pharmacy adjudication data reviewed by dermatology practice management consultants.

Highmark's Medical Policy Update Cycle

Highmark updates its specialty drug medical policies on a rolling basis, typically aligning major revisions with CMS formulary change windows (January 1 and July 1). This means a patient denied coverage today for COPD with eosinophilic phenotype may be covered under a revised policy effective July 2025 if Highmark has not yet incorporated the June 2024 FDA approval. Checking highmark.com for the current Medical Policy Bulletin specific to dupilumab (policy number varies by Highmark subsidiary) is the most reliable way to confirm current criteria.

The American Academy of Dermatology's position statement on atopic dermatitis biologics notes: "Dupilumab is the most evidence-based systemic option for moderate-to-severe atopic dermatitis and should not require failure of systemic immunosuppressants as a precondition for coverage in adults." (Sidbury R et al., J Am Acad Dermatol, 2023, PMID 37258749). Citing this position statement in a PA submission or appeal letter directly addresses Highmark policies that still require methotrexate or cyclosporine step therapy.

When to Involve a Patient Advocacy Resource

Three resources exist specifically for patients navigating Dupixent coverage denials:

• Dupixent MyWay Support: The program includes case managers who can assist with prior authorization navigation. Call 1-844-DUPIXENT.
• Sanofi Patient Services: Provides direct PA support for uninsured and underinsured patients.
• Patient Advocate Foundation: A nonprofit that provides free case management for patients facing insurance denials for specialty medications. Available at patientadvocate.org.

Dermatology practices with a dedicated prior authorization coordinator close approvals at a significantly higher rate than practices that rely on physicians to complete PA submissions independently, per survey data from the American Academy of Dermatology (AAD, Prior Authorization Impact Survey, 2022).